Trial · NCT01607671
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
NCT01607671, Phase 1, Withdrawn, Fraser Health
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%. Trials, record NCT01607671. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01607671
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
- NCT number
- NCT01607671
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Fraser Health
- Conditions
- Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy, Ischemic Optic Neuropathy, Optic Neuropathy, Anterior Ischemic
- Interventions
- Timolol maleate
- First posted
- 2012-05-30
- Last updated
- 2015-05-25
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Rate of patients during the one year study to assess feasibility of a larger study | 12 months | This is to define the feasabilty of the study design for a larger study. |
| Primary | Number of patients with adverse events | 12 months | |
| Secondary | Change in visual acuity at enrollment and three month follow up using a logMAR scale. | Enrolment, Within 48 hours of enrollment , 1 month, 3 months. | This will evaluate the change in visual acuity as a measure of visual function. |
| Secondary | Change in the mean deviation of actual versus predicted sensitivity of the visual field. | 48 hours after enrollment, 1 month, 3 months | Using a a Haag-Streit Octopus 900 with white on white TOP 30-2 visual field program, the mean deviation will be compared at various time points to assess for improving visual function as it relates to the field of vision. |
| Secondary | Change in Colour vision as measured by HRR colour plates. | Within 48 hours of enrollment, 1 month, 3 months | The total number of colour plates seen will be counted and compared to baseline as a measure of visual recovery as it effects colour vision. |
| Secondary | Change in contrast sensitivity will be measured using the Pelli-Robson contrast sensitivity chart. | 48 hours from enrollment, 1 month, 3 months. | The Pelli-Robson contrast sensitivity chart is another method to assess visual function. The change in total number of plates seen will be compared at the various time points. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01607671
GET https://conductscience.org/api/trials/v1/NCT01607671/registered